Intestinal inflammation
KPV is the C-terminal tripeptide of α-MSH and retains its anti-inflammatory activity without melanocortin receptor effects. Dalmasso 2008 showed oral KPV reduced colitis severity in DSS and TNBS rodent models via PepT1 transporter uptake. All evidence is preclinical — no human trial of KPV monotherapy has been published.
0 human studies · 8 animal studies
Key findings & citations
- Oral KPV reduced DSS-colitis and TNBS-colitis severity in mice (Dalmasso 2008).
- Mechanism: PepT1-mediated uptake into colonocytes and macrophages followed by NF-κB inhibition.
- Nanoparticle-targeted formulations (Xiao 2017) improve colon delivery in animal models.
- No published human trial in IBD or any inflammatory indication.
Our take
Mechanistically interesting but everything is rodents. Community use for gut and skin inflammation is built on extrapolation, not human data.